Skip to main content

Table 1 Patient demographics and disease characteristics

From: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer

Variable All patients (n = 208)
No. %
Age, years
 Median 58  
 Range 29–82
Sex
 Male 136 65.4
 Female 72 34.6
Smoking status
 Current 73 35.1
 Former 58 27.9
 Never 77 37.0
Histology
 Adenocarcinoma 164 78.8
 Squamous cell 32 15.4
 Other 12 5.8
Stage
 IIIB 15 7.2
 IV 193 92.8
ECOG PS
 0 17 8.2
 1 134 64.4
 2 57 27.4
First-line therapy
 GP 105 50.5
 IP 103 49.5
Salvage EGFR-TKI therapy
 Second-line 60 28.8
 Third-line 38 18.3
 No 110 52.9
EGFR mutations
 19DEL 38 18.3
 L858R 13 6.3
 Wild type 143 68.7
 Not determined 14 6.7
KRAS mutations
 Codon 12 8 3.8
 Codon 13 2 1.0
 Codon 61 2 1.0
 Wild type 123 59.1
 Not determined 73 35.1
  1. EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor
\